The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...

Chikungunya is a viral disease spread by mosquito bites; it causes fever, severe joint pain and rash on the body. Chikungunya occurs in Africa, Asia and the Indian sub continent.

Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first ...

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

About Chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and ...